Daewoong Pharmaceutical Co. LTD.
CompanySouth Korea
Daewoong Pharmaceutical Co. LTD. develops 3 assets, the furthest approved (ezetimibe in heterozygous familial hypercholesterolemia). Mostly small molecule acting on lipid and ceramide metabolism, HMGCR and AMPK signalling; based in South Korea.
- Assets
- 3
- Furthest
- Approved
- Trials
- 17
- Signals
- 1
Pipeline
3Inhibits ATP citrate lyase to reduce cholesterol biosynthesis
ApprovedSmall moleculeAMPK signallingLipid and ceramide metabolismheterozygous familial hypercholesterolemiahomozygous familial hypercholesterolemia
HMG-CoA reductase inhibitor lowering LDL cholesterol.
ApprovedSmall moleculeLipid and ceramide metabolismSLC5A2acute coronary syndrome (Phase 3)atherosclerosis (Phase 3)
Fixed-dose combination inhibiting HMG-CoA reductase, L-type calcium channels, and angiotensin II type 1 receptor
Phase 3Small moleculeLipid and ceramide metabolismAGTR1hyperlipidemiashypertension
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms8
- Trials21
- Signals7
- Similar companies6
Updated 7 Oct 2026 · 169 sources